Based on all these somewhat descriptive analyses, several authors suggested that BCR-mediated NFAT2 overexpression may be implicated in CLL pathobiology and may potentially be targeted for therapeutic purposes. Here, BCR is linked to B-cell chronic lymphocytic leukemia.